慢加急性肝衰竭患者预后相关免疫因素研究进展

高梦丹; 赵艳

doi:10.3969/j.issn.1001-5256.2017.12.047

慢加急性肝衰竭患者预后相关免疫因素研究进展

DOI: 10.3969/j.issn.1001-5256.2017.12.047

高梦丹,
赵艳

首都医科大学附属北京佑安医院临检中心

基金项目:

北京市医管局“扬帆计划”重点专业(ZYLX201711)；传染病相关疾病生物标志物北京市重点实验室(BZ0373)；丰台区科技项目(BJYAH2015YN15)；

详细信息

中图分类号: R575.3
计量
- 文章访问数: 1271
- HTML全文浏览量: 9
- PDF下载量: 397
- 被引次数: 0
出版历程
- 收稿日期: 2017-06-20
- 出版日期: 2017-12-20

Research advances in immune factors for the prognosis of patients with acute-on-chronic liver failure

Clinical Laboratory Center, Beijing You An Hospital, Capital Medical University

Research funding:

摘要

摘要: 慢加急性肝衰竭(ACLF)在我国较为常见,其发病机制复杂,临床救治困难,预后极差,多种因素会影响ACLF患者预后。从免疫细胞和细胞因子两个方面,阐述了其在ACLF中的变化及其对ACLF预后的影响,旨在探索与ACLF预后相关的新的生物标志物,从而对临床治疗进行干预,最终改善ACLF患者的预后。
- 肝功能衰竭 /
- 预后 /
- 免疫系统 /
- 细胞因子类 /
- 综述
Abstract: Acute-on-chronic liver failure ( ACLF) is commonly seen in China, with a complex pathogenesis, difficult clinical treatment, and poor prognosis. Many factors can affect the prognosis of patients with ACLF. This article elaborates on the changes in immune cells and cytokines in ACLF and their influence on the prognosis of ACLF, in order to explore new biomarkers associated with the prognosis of ACLF, provide guidance for clinical treatment, and finally improve the prognosis of patients with ACLF.
- liver failure /
- prognosis /
- immune system /
- cytokines /
- review

HTML全文

参考文献(43)

[1] Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association.Diagnostic and treatment guidelines for liver failure (2012 version) [J].Chin J Hepatol, 2013, 21 (3) :177-183. (in Chinese) 中华医学会感染病学分会肝衰竭与人工肝学组.肝衰竭诊治指南 (2012年版) [J].中华肝脏病杂志, 2013, 21 (3) :177-183.

[2]NING Q.Prospect and progression on study associated with severe acute exacerbation of chronic hepatitis B[J].Chin J Hepatol, 2010, 18 (2) :81-84. (in Chinese) 宁琴.乙型肝炎重症化研究现状和发展趋势[J].中华肝脏病杂志, 2010, 18 (2) :81-84.

[3]NING Q, ZHU L, YAN WM.Prewarning of severe acute aggravation of chronic hepatitis B[J].Chin J Hepatol, 2010, 18 (11) :805-807. (in Chinese) 宁琴, 朱琳, 严伟明.乙型肝炎重症化的早期预警[J].中华肝脏病杂志, 2010, 18 (11) :805-807.

[4]YI RT, NIU YH, LIU HL, et al.Natural killer group 2a expressed on both peripheral CD3-CD56+NK cells and CD3+CD8+T cells plays a pivotal negative regulatory role in the progression of hepatitis B virus-related acute-on-chronic liver failure[J].J Interferon Cytokine Res, 2016, 36 (12) :689-697.

[5]YE YN, LIU J, GAO ZL, et al.Decreases in activated CD8+Tcells in patients with severe hepatitis B are related to outcomes[J].Dig Dis Sci, 2015, 60 (1) :136-145.

[6] LIU XY, SHI F, WANG HF, et al.Research of PD-1 expression in CD8+T cell of periphera I blood with HBV-associated acute-on chronic liver failure[J].Chin J Exp Clin Virol, 2010, 24 (2) :125-127. (in Chinese) 刘晓燕, 石峰, 王慧芬, 等.PD-1受体在HBV-ACLF患者外周血CD8+T细胞上的表达研究[J].中华实验和临床病毒学杂志, 2010, 24 (2) :125-127.

[7]WASMUTH HE, KUNZ D, YAGMUR E, et al.Patients with acute-on-chronic liver failure display‘sepsis-like’immuneparalysis[J].Hepatology, 2005, 42 (2) :195-201.

[8]SHI F, TIEN P, WANG FS, et al.Skewed ratios between CD3+Tcells and monocytes are associated with poor prognosis in patients with HBV-related acute-on-chronic liver failure[J].Biochem Biophys Res Commun, 2010, 402 (1) :30-36.

[9]AGGARWAL S, GHILARDI N, XIE MH, et al.Interleukin-23promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17[J].Bio Chem, 2003, 278 (3) :1910-1914.

[10]IWAKURA Y, ISHIGAME H.The IL-23/IL-17 axis in inflammation[J].Clin Invest, 2006, 116 (5) :1218-1222.

[11]ZHANG GL, XIE DY, GAO ZL, et al.Imbalance of interleukin-17-producing CD4+T cells/regulatory T cells axis occurs in remission stage of patients with hepatitis B virus-related acute-onchronic liver failure[J].J Gastroenterol Hepatol, 2013, 28 (3) :513-521.

[12]LIANG XS, LI CZ, ZHOU Y, et al.Changes in circulating Foxp3+regulatory T cells and interleukin-17-producing T helper cells during HBV-related acute-on-chronic liver failure[J].Gastroenterol, 2014, 20 (26) :8558-8571.

[13]SHEN C, YAN WZ, ZHAO CY, et al.Increased CD4+CD25+regulatory T cells correlate with poor short-term outcomes in hepatitis B virus-related acute-on-chronic liver failure patients[J].J Microbiol Immunol Infect, 2015, 48 (2) :137-146.

[14]EYERICH S, EYERICH K, PENNINO D, et al.Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling[J].Clin Invest, 2009, 119 (12) :3573-3585.

[15]MO RD, WANG P, LAI R, et al.Persistently elevated circulating Th22 reversely correlates with prognosis in HBV-related acute-on-chronic liver failure[J].J Gastroenterol Hepatol, 2017, 32 (3) :677-686.

[16]BERNSMEIER C, TRIANTAFYLLOU E, BRENIG R, et al.CD14+CD15-HLA-DR-myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure[J].Hepatology, 2017.[Epub ahead of print]

[17]YE H, WANG LY, WANG K.Increased CD163 expression is associated with acute-on-chronic hepatitis B liver failure[J].Gastroenterol, 2013, 19 (18) :2818-2825.

[18]LAI JL, LIU YM, ZHOU YP, et al.Interleukin-1 receptor antagonist expression is inversely associated with outcomes of hepatitis B-related acute-on-chronic liver failure[J].Exp Ther Med, 2017, 13 (6) :2867-2875.

[19]DU XX, SHI Y, YANG Q, et al.DAMP molecular IL-33 augments monocytic inflammatory storm in hepatitis B-precipitated acute-on-chronic liver failure[J].Liver Int, 2017.[Epub ahead of print]

[20]LUO GC, HUANG YL, ZHANG GY, et al.Research on the relationship between serum cytokine levels and prognosis in patients with HBV-related acute-on-chronic liver failure[J].Lab Med, 2014, 29 (1) :26-30. (in Chinese) 罗光成, 黄云丽, 张国元, 等.HBV相关慢加急性肝衰竭患者血清细胞因子水平与疾病预后的关系研究[J].检验医学, 2014, 29 (1) :26-30.

[21]LU J, HE JQ.Association of the changes in the levels of interleukin-6, interleukin-10, and tumor necrosis factor-αwith hepatic encephalopathy in patients with acute-on-chronic liver failure[J].Pract Clin Med, 2016, 17 (10) :16-18. (in Chinese) 炉军, 何金秋.慢加急性肝衰竭患者IL-6、IL-10、TNF-α水平变化与肝性脑病的关系[J].实用临床医学, 2016, 17 (10) :16-18.

[22]SUDO K, YAMADA Y, SAITO K, et al.TNF-αand IL-6 signals from the bone marrow derived cells are necessary for normal murine liver regeneration[J].Biochim Biophys Acta, 2008, 1782 (11) :671-679.

[23]TILG H, MOSCHEN AR, KANEIDER NC.Pathways of liver injuryin alcoholic liver disease[J].Hepatology, 2011, 55 (5) :1159-1161.

[24]ALAM A, CHUN SUEN K, MA D.Acute-on-chronic liver failure:recent update[J].J Biomed Res, 2017, 31 (3) :1-18.

[25]HUOVILA AP, TURNER AJ, PELTO-HUIKKO M, et al.Shedding light on ADAM metalloproteinases[J].Trends Biochem Sci, 2005, 30 (7) :413-422.

[26]VALAYDON Z, PELLEGRINI M, THOMPSON A, et al.The role of tumour necrosis factor in hepatitis B infection:Jekyll and Hyde[J].Clin Transl Immunology, 2016, 5 (12) :e115.

[27]WANG ZL, GAO S, WANG K, et al.Demethylation of tumor necrosis factor-αconverting enzyme predicts poor prognosis in acuteon-chronic hepatitis B liver failure[J].Clin Res Hepatol Gastroenterol, 2016, 40 (4) :457-464.

[28]YU XP, ZHENG YJ, DENG Y, et al.Serum interleukin (IL) -9and IL-10, but not T-helper 9 (Th9) cells, are associated with survival of patients with acute-on-chronic hepatitis B liver failure[J].Medicine, 2016, 95 (16) :e3405.

[29]ZOU ZS, LI BS, WANG FS, et al.Imbalanced intrahepatic cytokine expression of interferon-[gamma], tumor necrosis factor-[alpha], and interleukin-10 in patients with acute-on-chronic liver failure associated with hepatitis B virus infection[J].Clin Gastroenterol, 2009, 43 (2) :182-190.

[30]BERRY PA, ANTONIADES CG, HUSSAIN MJ, et al.Admission levels andearly changes in serum interleukin-10 are predictive of poor outcome in acute Iiver failure and decompensated cirrhosis[J].Liver Int, 2010, 30 (5) :733-740.

[31]MONNERET G, FINCK ME, VENET F, et al.The anti-inflammatory response dominates after septic shock:association of low monoeyte HLA-DR expression and high interleukin-10 concentration[J].Immunol Lett, 2004, 95 (2) :193-198.

[32]HU X, MA S, HOU JL, et al.Interleukin-21 is upregulated in hepatitis B-related acute-on-chronic liver failure and associated with severity of liver disease[J].J Viral Hepat, 2011, 18 (7) :458-467.

[33]BAO SX, ZHENG JM, LI N, et al.Role of interleukin-23 in monocyte-derived dendritic cells of HBV-related acute-onchronic liver failure and its correlation with the severity of liver damage[J].Clin Res Hepatol Gastroenterol, 2017, 41 (2) :147-155.

[34]MIWA Y, HARRISON PM, FARZANEH F, et al.Plasma levels and hepatic mRNA expression of transforming growth factor-beta1in patients with fulminant hepatic failure[J].Hepatol, 1997, 27 (5) :780-788.

[35]YOSHIMOTO N, TOGO S, KUBOTA T, et al.Role of transforming growth factor-beta1 (TGF-beta1) in endotoxin-induced hepatic failure after extensive hepatectomy in rats[J].Endotoxin Res, 2005, 11 (1) :33-39.

[36]YU XP, GUO RY, SU ZJ, et al.The transforming growth factorβ1/Interleukin-31 pathway is upregulated in patients with hepatitis B virus-related acute-on-chronic liver failure and is associated with disease severity and survival[J].Clin Vaccine Immunol, 2015, 22 (5) :484-492.

[37]GARG V, GARG H, KHAN A, et al.Granulocyte-colony stimulatingfactor mobilizes CD34 (+) cells and improves survival of patients with acute-on-chronic liver failure[J].Gastroenterology, 2012, 142 (3) :505-512.

[38]DUAN XZ, LIU FF, TONG JJ, et al.Granulocyte-colony stimulating factor therapy improves survival in patients withhepatitis B virus-associated acute-on-chronic liver failure[J].Gastroenterol, 2013, 19 (7) :1104-1110.

[39]KHANAM A, TREHANPATI N, GARG V, et al.Altered frequencies of dendritic cells and IFN gamma-secreting T cells with granulocyte colony-stimulating factor (G-CSF) therapy in acute-on-chronic liver failure[J].Liver Int, 2014, 34 (4) :505-513.

[40]ANDERLINI P, PRZEPIORKA D, CHAMPLIN R, et al.Biologic andclinical effects of granulocyte colony-stimulating factor innormal individuals[J].Blood, 1996, 88 (8) :2819-2825.

[41]de HAAS M, KERST JM, van der SCHOOT CE, et al.Granulocytecolony-stimulating factor administration to healthy volunteers:analysis of the immediate activating effects on circulating neutrophils[J].Blood, 1994, 84 (11) :3885-3894.

[42]THOMAS JA, POPE C, WOJTACHA D, et al.Macrophage therapyfor murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function[J].Hepatology, 2011, 53 (6) :2003-2015.

[43]CHAVEZ-TAPIA NC, MENDIOLA-PASTRANA I, ORNELAS-ARROYO VJ, et al.Granulocyte-colony stimulating factor foracuteonchronicliver failure:systematic review andmeta-analysis[J].Ann Hepatol, 2015, 14 (5) :631-641.

施引文献

资源附件(0)

访问统计